Next Article in Journal
SARS-CoV-2 Droplet and Airborne Transmission Heterogeneity
Previous Article in Journal
Prevalence and Methods for Assessment of Oropharyngeal Dysphagia in Older Adults: A Systematic Review and Meta-Analysis
Previous Article in Special Issue
Canonical TGFβ Signaling and Its Contribution to Endometrial Cancer Development and Progression—Underestimated Target of Anticancer Strategies
Review

Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review

1
Department of Obstetrics and Gynecology, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan
2
Translational Research Program, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan
*
Author to whom correspondence should be addressed.
Academic Editors: Anis Feki and Youssef Hibaoui
J. Clin. Med. 2022, 11(9), 2606; https://doi.org/10.3390/jcm11092606
Received: 28 March 2022 / Revised: 29 April 2022 / Accepted: 4 May 2022 / Published: 6 May 2022
(This article belongs to the Special Issue Human Endometrial Development and Disease)
Background: Because patient-derived xenograft (PDX) models resemble the original tumors, they can be used as platforms to find target agents for precision medicine and to study characteristics of tumor biology such as clonal evolution and microenvironment interactions. The aim of this review was to identify articles on endometrial cancer PDXs (EC-PDXs) and verify the methodology and outcomes. Methods: We used PubMed to research and identify articles on EC-PDX. The data were analyzed descriptively. Results: Post literature review, eight studies were selected for the systematic review. Eighty-five EC-PDXs were established from 173 patients with EC, with a total success rate of 49.1%. A 1–10 mm3 fragment was usually implanted. Fresh-fragment implantation had higher success rates than using overnight-stored or frozen fragments. Primary tumors were successfully established with subcutaneous implantation, but metastasis rarely occurred; orthotopic implantation via minced tumor cell injection was better for metastatic models. The success rate did not correspond to immunodeficiency grades, and PDXs using nude mice reduced costs. The tumor growth period ranged from 2 weeks to 13 months. Similar characteristics were observed between primary tumors and PDXs, including pathological findings, gene mutations, and gene expression. Conclusion: EC-PDXs are promising tools for translational research because they closely resemble the features of tumors in patients and retain molecular and histological features of the disease. View Full-Text
Keywords: endometrial cancer; patient-derived xenograft; PDX endometrial cancer; patient-derived xenograft; PDX
Show Figures

Figure 1

MDPI and ACS Style

Tanaka, T.; Nishie, R.; Ueda, S.; Miyamoto, S.; Hashida, S.; Konishi, H.; Terada, S.; Kogata, Y.; Sasaki, H.; Tsunetoh, S.; Taniguchi, K.; Komura, K.; Ohmichi, M. Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review. J. Clin. Med. 2022, 11, 2606. https://doi.org/10.3390/jcm11092606

AMA Style

Tanaka T, Nishie R, Ueda S, Miyamoto S, Hashida S, Konishi H, Terada S, Kogata Y, Sasaki H, Tsunetoh S, Taniguchi K, Komura K, Ohmichi M. Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review. Journal of Clinical Medicine. 2022; 11(9):2606. https://doi.org/10.3390/jcm11092606

Chicago/Turabian Style

Tanaka, Tomohito, Ruri Nishie, Shoko Ueda, Shunsuke Miyamoto, Sousuke Hashida, Hiromi Konishi, Shinichi Terada, Yuhei Kogata, Hiroshi Sasaki, Satoshi Tsunetoh, Kohei Taniguchi, Kazumasa Komura, and Masahide Ohmichi. 2022. "Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review" Journal of Clinical Medicine 11, no. 9: 2606. https://doi.org/10.3390/jcm11092606

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop